Bio-Path Holdings ( (BPTH) ) has released a notification of late filing.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Bio-Path Holdings, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending September 30, 2025. The delay is primarily due to a change in management, which has impacted the timely compilation of necessary information. The company expects to file the report within five calendar days following the original due date. There are no anticipated significant changes in financial results compared to the previous year. Bio-Path Holdings is committed to maintaining compliance and has authorized this notification through its CEO, Vikram Grover.
The most recent analyst rating on (BPTH) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Bio-Path Holdings stock, see the BPTH Stock Forecast page.
Spark’s Take on BPTH Stock
According to Spark, TipRanks’ AI Analyst, BPTH is a Underperform.
Bio-Path Holdings’ stock is significantly challenged by poor financial performance, characterized by no revenue and high cash burn. The technical indicators also suggest a bearish trend. However, the promising pre-clinical results offer a glimmer of hope for future prospects. The negative P/E ratio and lack of dividend yield further contribute to a low valuation score. Overall, the stock is risky, with financial sustainability being a major concern.
To see Spark’s full report on BPTH stock, click here.
More about Bio-Path Holdings
Average Trading Volume: 66,565
Technical Sentiment Signal: Sell
Current Market Cap: $809.9K
Find detailed analytics on BPTH stock on TipRanks’ Stock Analysis page.